A family foundation, not a fund, is paying for USC's cardiac cell therapy trials

The Marcus Foundation has given $28.7 million to Chuck Murry, director of the University of Southern California's Stem Cell Center, to advance clinical trials of stem cell-based therapies that regenerate tissue damaged by a heart attack ^[1]. What is notable is not the biology but the balance sheet: the trial stage, historically the point where academic work is handed to a company or abandoned, is being funded here by a private family foundation established in 1989 by Bernie and Billi Marcus ^[1][2].

The gift is the largest the foundation has made to USC and one of the largest it has made to academic medicine ^[3]. Since 1989 the foundation has granted more than $2.7 billion across more than 3,500 grants ^[4], which on those stated figures puts the average grant near $770,000 ^[1] and makes this one roughly 37 times that size ^[2]. It also exceeds the foundation's two other recent large medical commitments: $25.9 million in 2024 for stroke research at Emory University School of Medicine and Grady Health System's Marcus Stroke and Neuroscience Center ^[5], about 11 percent smaller than the USC grant ^[3], and $20 million in 2019 to establish a Department of Integrative Medicine and Nutritional Sciences at Jefferson's Sidney Kimmel Medical College ^[6].

The stated rationale is stage, not discovery. According to Jonathan Simons, the foundation's chief science officer, Murry and his team "have advanced gene-edited cellular therapy to the point that the time is right to support cells as living medicine in this new form of treatment" ^[7]. That is the only technical detail disclosed. The announcement as reported does not specify trial phase, patient numbers, endpoints, timelines, or any industry or venture co-funder, so operators reading this as a validation event should be careful about how much they are reading in.

Two things make the grant more than a one-off. First, it sits inside a declared program: the foundation names five biomedical priorities, including stem cell research and regenerative medicine and cardiovascular disease ^[8]. Second, the foundation's own account of its method is concentration rather than opportunism. Bernie Marcus told Philanthropy Roundtable in 2012 that he had decided "to narrow the field to those things that I was really, truly interested in," moving away from what he called a "buckshot approach" ^[9], and trustee Mike Leven said that without discipline "you're going to overgive and underachieve" ^[10]. A funder with stated priorities and a $2.7 billion track record ^[4] is a more predictable counterparty than a crossover fund, and a competing academic center or a small cardiac cell therapy company should treat it as a live source of non-dilutive clinical capital.

The founder is gone. Marcus died in November 2024 at 95, with an estimated net worth of $11 billion ^[11], and the foundation has continued to write large medical cheques since ^[1]. Its earliest grant was roughly $110,000 to Emory's Egleston Children's Research ^[12]; it also seeded Autism Speaks in 2005 and built named centers at Grady, Children's Healthcare of Atlanta and the University of Colorado Anschutz Medical Campus ^[13].

Watch for the trial registration and phase, which will show whether $28.7 million buys a first-in-human study or a powered efficacy trial. Watch whether a pharma partner appears at readout, which would tell you the grant substituted for early venture money rather than replaced it. And watch USC's next disclosure on the Stem Cell Center's funding mix, since the foundation's own priority list suggests this is unlikely to be its last cardiac cell therapy grant ^[8].